Pharming (PHAR) Cost of Revenue (2020 - 2026)

Pharming (PHAR) has 7 years of Cost of Revenue data on file, last reported at $21.2 million in Q2 2026.

• Quarterly Cost of Revenue rose 22.52% year-over-year to $21.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $28200.0 billion (up 314.7% YoY) and the FY2025 annual result came in at $45.5 million, up 28.53% from the prior year.
• Cost of Revenue climbed to $21.2 million in Q2 2026, from $0.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $21100.0 billion in Q4 2025 to a low of $0.0 in Q1 2026.
• A 5-year average of $2261.1 billion and a median of $16.8 million in 2024 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2025 — Cost of Revenue soared 99248647.91% — and 2026, when it plunged 100.0%.
• Tracing PHAR's Cost of Revenue over 5 years: stood at $11.3 million in 2022, then jumped by 123.12% to $25.2 million in 2023, then jumped by 40.41% to $35.4 million in 2024, then soared by 59606103.57% to $21100.0 billion in 2025, then sank by 100.0% to $21.2 million in 2026.
• The last three Cost of Revenue figures came in at $21.2 million (Q2 2026), $0.0 (Q1 2026), and $21100.0 billion (Q4 2025), per Business Quant data.